- Research article
- Open Access
- Open Peer Review
The role of p19 and p21 H-Ras proteins and mutants in miRNA expression in cancer and a Costello syndrome cell model
© García-Cruz et al. 2015
- Received: 21 January 2015
- Accepted: 1 June 2015
- Published: 3 July 2015
P19 H-Ras, a second product derived from the H-Ras gene by alternative splicing, induces a G1/S phase delay, thereby maintaining cells in a reversible quiescence state. When P21 H-Ras is mutated in tumour cells, the alternative protein P19 H-Ras is also mutated. The H-Ras mutation Q61L is frequently detected in different tumours, which acts as constitutive activator of Ras functions and is considered to be a strong activating mutant. Additionally, a rare congenital disorder named Costello Syndrome, is described as a H-Ras disorder in children, mainly due to mutation G12S in p19 and p21 H-Ras proteins, which is present in 90 % of the Costello Syndrome patients. Our aim is to better understand the role of p19 and p21 H-Ras proteins in the cancer and Costello Syndrome development, concerning the miRNAs expression.
Total miRNAs expression regulated by H-Ras proteins were first analyzed in human miRNA microarrays assays. Previously selected miRNAs, were further analyzed in developed cell lines containing H-Ras protein mutants, that included the G12S Costello Syndrome mutant, with PCR Real-Time Taq Man miRNA Assays primers.
This study describes how p19 affects the RNA world and shows that: i) miR-342, miR-206, miR-330, miR-138 and miR-99b are upregulated by p19 but not by p19W164A mutant; ii) anti-miR-206 can restore the G2 phase in the presence of p19; iii) p19 and p21Q61L regulate their own alternative splicing; iv) miR-206 and miR-138 are differentially regulated by p19 and p21 H-Ras and v) P19G12S Costello mutants show a clear upregulation of miR-374, miR-126, miR-342, miR-330, miR-335 and let-7.
These results allow us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and open up a new line of study to understand the consequences of this mutation on Costello syndrome. Furthermore, they suggest that oncogenes may have a sufficiently important impact on miRNA expression to promote the development of numerous cancers.
- Alternative splicing
- Costello syndrome
- H-ras mutants
Ras, an important family of proto-oncogenes in humans, consists of three members (H-Ras, N-Ras and K-Ras) located on human chromosomes 1, 11 and 12 respectively [1–3]. Indeed, Ras gene mutations have been implicated in up to 30 % of all tumours tested. These mutations are different and depend on the tissues involved but most commonly result in pancreatic (90 %) and colon and thyroid tumours (50 %), and lung and myeloid leukemias (30 %). A point mutation in Ras codons converts these genes into active oncogenes as a result of decreased GTPase activity, thereby restricting the easy interchange of GDP to GTP and resulting in a constitutive activation of the downstream pathways, or loss of GAP function. Ras mutated proteins are indirectly involved in metastasic phenotype development as they promote the acquisition of cumulative alterations in cellular pathways which result in cytoskeletal rearrangements, loss of cell adhesion (metalloprotease overexpression), tissue invasion, extravasation into lymphatic and blood vessels, and finally apoptosis evasion .
The H-Ras gene codifies for two different proteins, namely p19 H-Ras and p21 H-Ras, by alternative splicing [5–7]. The mRNA structures of these alternative sequences are identical in their first coding exons (called 1, 2, 3 and 4A) and have two non-codifying exons (0 and 4B located at the 5′-UTR and 3′-UTR regions, respectively) separated by intronic regions designated as A-E. The alternative exon, known as IDX (intron-D-exon, 82 nucleotides), is located between exons 3 and 4A. The pre-mRNA H-Ras is processed into two mRNAs, namely p21 mRNA, which excludes the IDX exon, and p19 mRNA, which includes it [5–7]. p19 mRNA therefore codes for a shorter protein than p21 mRNA. Furthermore, since IDX exon contains a premature stop codon, p19 does not contain the CAAX motif . p19 H-Ras induces a G1/S phase delay, thereby maintaining cells in a reversible quiescence state . p19 Binds to RACK1 and regulates telomerase activity upon interaction with p73α/β proteins as well as inducing hypophosphorylation of Akt and p70S6K and upregulating FOX1 [6, 7]. Although p19 overexpression does not induce apoptosis , Kim et al. have shown that it stimulates p73β-induced apoptosis when both proteins are simultaneously overexpressed . RNAi of p19 increases cell growth, thereby having an opposite effect to the delay in the G1/S phase described above . Other authors showed that p19 represses proliferation on non-small cell lung cancer through interaction with neuron-specific enolase (NSE) .
P19 was first described from in T24/EJ bladder carcinoma cell line that contains, in addition to G12V mutation, a small number of other nucleotide changes including an adenine (A) to guanine (G) mutation at position 2714. This latter region was showed to regulate the alternative splicing of H-Ras into two proteins, p21 and p19. The 2719 mutation decresed the p19 expression, and this mutation promotes 10-fold increase of p21 H-Ras levels and a corresponding increase of the transforming efficiency of structurally activated alleles [5, 10].
The H-Ras mutation Q61L is frequently detected in different tumour cell lines, where it acts as a constitutive activator of the Ras-signalling pathway and is considered to be a strong activating mutant by decreasing GTPAse activity and increasing GDP/GTP exchange [1, 11, 12]. G12S, another important H-Ras mutation is, present in more than 90 % of patients with Costello Syndrome (CS), a rare congenital disorder caused by germ-line activation of H-Ras oncogenes that affects both p19 and p21 H-Ras . CS is characterized by severe failure-to-thrive, cardiac abnormalities, including tachyarrhythmia and hypertrophic cardiomyopathy, a predisposition to papillomata and malignant tumours, and neurologic abnormalities, including nystagmus, hypotonia developmental delay, and mental retardation [14–18].
To better understand the role of p19 and p21 H-Ras proteins in the development of cancer, we transfected HeLa cells with p19 and p21 mutant sequences, which were reported in the literature to be commonly detected in tumour cell lines and in CS (G12S). We also evaluated the expression of selected miRNAs  involved in some aspects of metastasis and others related with aggressive small cell lung cancer.
Cell lines, cell transfection and antibodies
HeLa cells were cultured and transiently transfected as described elsewhere [6, 7]. Knock-out murine embryonic fibroblasts (MEFs) H-Ras−/− (KO) and double knock-out MEFs H-Ras−/− plus N-Ras−/− (DKO) were obtained from Dr. E. Santos’s laboratory . KO and DKO cell lines, stably expressing pEGFP (negative control), pEGFP-p19 and pEGFP-21, were obtained by transfecting the fibroblasts with the specific vector and selecting with geneticin.
pEGFP-p19 and -p21, pRK5-p19 and pRK5-p19W164A have been described previously [6, 7], therefore the other pRK5 plasmids were obtained in a similar manner [6, 7]. Other point mutations of p19 H-Ras and p21 H-Ras were performed by polymerase chain reaction site-directed mutagenesis using the QuickChange® Site-Directed mutagenesis kit from Stratagene.
Isolation of small RNAs
miRNAs were extracted using the miRVANA™ miRNA isolation kit from Ambion Inc. (Austin, Tx). Isolation was performed as described by the manufacturer’s protocol.
miRNA microarrays were performed as described previously .
miRNA Reverse Transcriptase (RT) reaction
cDNA was reverse-transcribed from enriched miRNA samples (miRVANA kit) using specific miRNA primers from the Taq Man MicroRNA Assay and reagents from the Taq Man MicroRNA RT kit (AB Applied Bio systems) according to the manufacturer’s instructions. Briefly, 1.33 μL of each resulting cDNA was amplified by PCR using Taq Man MicroRNA Assay primers with the Taq Man Universal Non amperase PCR Master Mix (in a total volume of 20 μL) and analyzed with a 7500 ABI PRISM Sequence Detector System according to the manufacturer’s instructions. miRNA expression was calculated from the relevant signals by normalization with respect to the signal for U18 (for HeLa cells) and U6 for MEFs. Stem-loop quantitative RT-PCR for mature miRNAs was performed as described previously using an Applied Biosystems ABI 7500 Real Time PCR system. All RT-PCR reactions were run in triplicate and gene expression, relative to U18, calculated using the 2-ΔΔCt method .
Real time TAQMAN RT-PCR assays of mRNAs
Total RNA was extracted from 10 × 105 HeLa cells using TRIZOL reagent (Life Technologies, Inc.), as described previously. cDNA was reverse-transcribed from total RNA samples using SuperScriptIII® from Invitrogen. The resulting cDNA was amplified by PCR using Taq Man Assay primers with the Taq Man Universal Non-amperase PCR Master Mix and analyzed with a 7500 ABI PRISM Sequence Detector System according to the manufacturer’s instructions. mRNA expression was calculated from the relevant signals by normalization with respect to the signal for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA expression. The assay numbers for exons E3-IDX p19 H-Ras (Hs00978053_g1), E4A-E4B H-Ras total (Hs00978051_g1) and E3-E4A p21 H-Ras (Hs00610483_m1) and for GAPDH (HS99999905_m1 housekeeping) were supplied by Applied Biosystems Gene Expression Assays (Applied Biosystems). Assays were run with Taqman Universal.
Western blot analysis, cell-proliferation assay and determination of cell-cycle phase percentages
No ethics approval was required for aspects of this study.
P19 overexpression regulates specific miRNA expression
H-Ras mutants alter the H-Ras splicing rate
P19 alters miRNAs expression but not the cell growth in H-Ras(−/−) KO cell lines
The p19 CS mutant G12S alters miRNA expression
Homeostatic regulation of H-Ras
Although p21 H-Ras mutants have been extensively studied, this is not the case for specific p19 H-Ras mutants. However, it is known that a mutation in the 5′ splice-site of the IDX exon of H-Ras (position 2719, A to G change) induces a 10-fold increase in p21 H-Ras level and a corresponding increase in the transforming activity in a bladder carcinoma cell line . In addition, we have previously reported that the mouse NIH 3 T3 cell contains a mutation at position 165 which causes a D to G change . p19 overexpression activates full-length total H-Ras and p21, although the endogenous p19:p21 ratio due to alternative splicing remains relatively unchanged (Fig. 2). This H-Ras and p21 activation is dependent on the W164A amino acid (Fig. 2). Thus, whereas the specific p19mut expression reverts endogenous total H-Ras to basal levels, p19mut alters alternative splicing in favor of p21. In this study, we also found that although the Q61L mutation in p21 does not affect endogenous total H-Ras expression, the Q61L mutation on p21 produces a clear change in the p19:p21 ratio by doubling the amount of p19 mRNA compared to wild-type. We can therefore conclude that the observed altered alternative splicing may act as a homeostatic response mechanism. We have also found that few proteins or miRNA genes are up- or downregulated when p19 is overexpressed (but not with the specific p19mut overexpression), showed in this work and . Indeed, the response mechanisms described in this work when p19, p19mut or the p21 mutant are overexpressed correlate well with observations in H-Ras knockout (KO) mice. These KO mice were found to be viable  and fibroblasts obtained from them had few genes that modified their expression . These findings indicate that a cellular response mechanism is in place that overcomes the lack of H-Ras, thereby allowing the mice to survive, and that a strong homeostatic mechanism plays a role in controlling p21 and p19 levels, as p21 drives cell proliferation whereas p19 maintains a reversible cellular quiescence state .
The role of p19 in cancer and metastasis processes
It may be significant that H-Ras is regulated by miRNAs, such as the let-7 miRNA family [27, 29], and that the alternative splicing of H-Ras, which favors p19 over p21, has consequences as regards the levels of certain miRNAs (Fig. 1a and Additional file 1). Two of the miRNAs upregulated by p19 (Additional file 1) have previously been reported to be of significant interest in cancer studies: miR-342 is one of the miRNA markers for acute promyelocytic leukemia [30, 31] and miR-206 suppresses ERα in breast cancer cell lines and also plays a role in muscular dystrophy [32–34]. miR-335, miR-206 and miR-126 have been shown to significantly reduce the ability of certain cells to metastasize to the lung [23, 35]. These latter results have driven us to further study the regulation of miR-206 by H-Ras proteins as overexpression of p19 causes G1/S delay  and upregulates miR-206 (Fig. 1a). We are aware of the limitations of those studies performed with overexpression of a CS mutant. Having this point in mind, we presented here experiments with KO H-Ras(−/−) DKO H-Ras(−/−)/N-Ras(−/−) that stably express p21 or p19. Additionally, we obtained some preliminary results of miRNAs Taqman RT-PCR expression profile of G12S or G12A endogenous p19 and p21 proteins in fibroblasts cell lines established from CS tumour patients. Those results showed that miR-330, miR-335 and miR-374 are statiscaly and significally overexpressed in those CS patients cells, and thus they are putative cadidates to be miRNAs overexpressed in CS patients (R. García-Cruz and K. Sol-Church, personnel communication). Herein we have shown that combining p19 overexpression with a miR-206 inhibitor results in a partial decrease of the G1 phase with a clear recovery of the G2 phase, thus indicating that miR-206 is one of the factors contributing to the delay of the G1/S phase. Additionally, we have shown that miR-206 is regulated by the alternative splicing of H-Ras (Fig. 3a) as the ovexpression of p19 upregulates miR-206 more effectively than p21 H-Ras when pEGPP-19 and pEGPP-21 are stably expressed in KO H-Ras(−/−). miR-138, a miRNA that suppresses invasion and promotes apoptosis in some carcinoma cells , was also studied. Figure 3b, c show that miR-138 is clearly upregulated in KO H-Ras(−/−) mice that stably express pEGPP-19, whereas it is unaffected in KO H-Ras(−/−) mice that stably express pEGPP-21 (Fig. 3b). This observation was corroborated by the transient expression of both proteins (Fig. 3c). Finally, we also corroborated our previous studies in which we demonstrated that p19 H-Ras does not induce growth using DKO H-Ras/N-Ras(−/−)/(−/−) mice that stably express pEGPP-19 (see Fig. 4). As we showed here that miR-206 regulates cell growth (being these observations in agreement with previous published results, see below) we discuss here our a putative protein 3′-UTR target that could be having a role on these cell growth regulation. Adams et al. have indentified ERα as a direct miR-206 target, and further demonstrated that miR-206 inhibited the mRNA and protein expression of ERα in human ovarian cells . Additionally, expression of miR-206 has been showed to inhibit cellular proliferation and to disturb invasion in ERα–positive endometrial carcinoma cells .
H-Ras mutants have been described as a potential marker for CS [15, 38, 39], although the mutations in IDX sequences and the rasISS1 splicing silencer described in  have not been observed in several patients with this CS (K. Sol-Church, personnel communication). This finding strongly suggests that H-Ras-related mutations in CS are likely to be found in the common amino acid sequences and thereby affect the complementary functions of p21 and p19. We can therefore conclude that both, p21 and p19, must malfunction in order for a subject to develop CS. Around 90 % of CS patients have the G to A mutation that results in the G12S amino acid change. We therefore tested how this mutation affects a selected group of cancer-related miRNAs and found a significant upregulation by p19 H-Ras G12S in all cases. This allowed us to conclude that the H-Ras G12S mutation plays an important role in miRNA expression and therefore opens up a new line of study to understand the consequences of this mutation on CS. Furthermore, this finding has further consequences for many cancers as our results indicate that oncogenes may have a sufficiently important impact on miRNA expression to promote their development.
Availability of supporting data
Additional file 1 include an additional table. Microarray data accession number: ETABM-494.
The authors would also like to thank Dr. Ruth Willmott for revising and discussing the manuscript, and Marta Casado for technical help and discussion. We acknowledge support of the publication fee by the CSIC Open Access Publication Support Initiative through its Unit of Information Resources for Research (URICI).
This work was supported by the Plan Nacional (MEC) BFU2005-00701, FIS PI080007 and the Fundación Eugenio Rodríguez Pascual. M.C. was funded by an Fmed MMA fellowship.
- Lowy DR, Willumsen BM. Function and regulation of ras. Annu Rev Biochem. 1993;62(3):851–91.PubMedGoogle Scholar
- Wennerberg K, Rossman KL, Der CJ. The Ras superfamily at a glance. J Cell Sci. 2005;118(Pt 5):843–6.PubMedGoogle Scholar
- Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets. 2013;17(5):507–31. doi:10.1517/14728222.2013.764990.PubMedPubMed CentralGoogle Scholar
- HernandezAlcoceba R, del Peso L, Lacal JC. The Ras family of GTPases in cancer cell invasion. Cell Mol Life Sci. 2000;57(1):65–76.Google Scholar
- Cohen JB, Broz SD, Levinson AD. Expression of the H-ras proto-oncogene is controlled by alternative splicing. Cell. 1989;58(3):461–72.PubMedGoogle Scholar
- Guil S, de La Iglesia N, Fernandez-Larrea J, Cifuentes D, Ferrer JC, Guinovart JJ, et al. Alternative splicing of the human proto-oncogene c-H-ras renders a new Ras family protein that trafficks to cytoplasm and nucleus. Cancer Res. 2003;63(17):5178–87.PubMedGoogle Scholar
- Camats M, Kokolo M, Heesom KJ, Ladomery M, Bach-Elias M. P19 H-ras induces G1/S phase delay maintaining cells in a reversible quiescence state. PLoS One. 2009;4(12):e8513.PubMedPubMed CentralGoogle Scholar
- Kim JW, Kim WH, Jeong MH, Jang SM, Song KH, Park SI, et al. p19(ras) amplifies p73beta-induced apoptosis through mitochondrial pathway. Biochem Biophys Res Commun. 2008;373(1):146–50.PubMedGoogle Scholar
- Jang SM, Kim JW, Kim CH, Kim D, Rhee S, Choi KH. p19(ras) Represses proliferation of non-small cell lung cancer possibly through interaction with Neuron-Specific Enolase (NSE). Cancer Lett. 2010;289(1):91–8. doi:10.1016/j.canlet.2009.08.005.PubMedGoogle Scholar
- Cohen JB, Levinson AD. A point mutation in the last intron responsible for increased expression and transforming activity of the c-Ha-ras oncogene. Nature. 1988;334(6178):119–24.PubMedGoogle Scholar
- Muraoka S, Shima F, Araki M, Inoue T, Yoshimoto A, Ijiri Y, et al. Crystal structures of the state 1 conformations of the GTP-bound H-Ras protein and its oncogenic G12V and Q61L mutants. FEBS Lett. 2012;586(12):1715–8. doi:10.1016/j.febslet.2012.04.058.PubMedGoogle Scholar
- Yang D, Wang MT, Tang Y, Chen Y, Jiang H, Jones TT, et al. Impairment of mitochondrial respiration in mouse fibroblasts by oncogenic H-RAS(Q61L). Cancer Biol Ther. 2010;9(2):122–33.PubMedPubMed CentralGoogle Scholar
- Lin AE, Rauen KA, Gripp KW, Carey JC. Clarification of previously reported Costello syndrome patients. Am J Med Genet A. 2008;146(7):940–3.Google Scholar
- Gripp KW, Lin AE, Stabley DL, Nicholson L, Scott Jr CI, Doyle D, et al. HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A. 2006;140(1):1–7.PubMedGoogle Scholar
- Gripp KW, Stabley DL, Nicholson L, Hoffman JD, Sol-Church K. Somatic mosaicism for an HRAS mutation causes Costello syndrome. Am J Med Genet A. 2006;140(20):2163–9.PubMedGoogle Scholar
- Sol-Church K, Stabley DL, Nicholson L, Gonzalez IL, Gripp KW. Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat. 2006;27(8):736–41.PubMedGoogle Scholar
- Niemeyer CM. RAS diseases in children. Haematologica. 2014;99(11):1653–62. doi:10.3324/haematol.2014.114595.PubMedPubMed CentralGoogle Scholar
- Morice-Picard F, Ezzedine K, Delrue MA, Arveiler B, Fergelot P, Taieb A, et al. Cutaneous manifestations in Costello and cardiofaciocutaneous syndrome: report of 18 cases and literature review. Pediatr Dermatol. 2013;30(6):665–73. doi:10.1111/pde.12171.PubMedGoogle Scholar
- Felekkis K, Touvana E, Stefanou C, Deltas C. microRNAs: a newly described class of encoded molecules that play a role in health and disease. Hippokratia. 2010;14(4):236–40.PubMedPubMed CentralGoogle Scholar
- Castellano E, De Las RJ, Guerrero C, Santos E. Transcriptional networks of knockout cell lines identify functional specificities of H-Ras and N-Ras: significant involvement of N-Ras in biotic and defense responses. Oncogene. 2007;26(6):917–33.PubMedGoogle Scholar
- Liu CG, Calin GA, Meloon B, Gamliel N, Sevignani C, Ferracin M, et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc Natl Acad Sci U S A. 2004;101(26):9740–4.PubMedPubMed CentralGoogle Scholar
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 2001;25(4):402–8.PubMedGoogle Scholar
- Tavazoie SF, Alarcon C, Oskarsson T, Padua D, Wang Q, Bos PD, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147–52.PubMedPubMed CentralGoogle Scholar
- Guil S, Gattoni R, Carrascal M, Abián J, Stévenin J, Bach-Elias M. Roles of hnRNP A1, SR proteins, and p68 Helicase in c-H-ras Alternative Splicing Regulation. Mol Cell Biol. 2003;23(8):2927–41.PubMedPubMed CentralGoogle Scholar
- Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet. 2005;37(10):1038–40.PubMedGoogle Scholar
- Miko E, Czimmerer Z, Csanky E, Boros G, Buslig J, Dezso B, et al. Differentially expressed microRNAs in small cell lung cancer. Exp Lung Res. 2009;35(8):646–64.PubMedGoogle Scholar
- Bussing I, Slack FJ, Grosshans H. let-7 microRNAs in development, stem cells and cancer. Trends Mol Med. 2008;14(9):400–9.PubMedGoogle Scholar
- Esteban LM, Vicario-Abejon C, Fernandez-Salguero P, Fernandez-Medarde A, Swaminathan N, Yienger K, et al. Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol Cell Biol. 2001;21(5):1444–52.PubMedPubMed CentralGoogle Scholar
- Chiu SC, Chung HY, Cho DY, Chan TM, Liu MC, Huang HM, et al. Therapeutic potential of microRNA let-7: tumor suppression or impeding normal stemness. Cell Transplant. 2014;23(4–5):459–69. doi:10.3727/096368914X678418.PubMedGoogle Scholar
- Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene. 2007.Google Scholar
- Mosakhani N, Räty R, Tyybakinoja A, Karjalainen-Lindsberg M, Elonen ET, Knuutila S. MicroRNA Profiling in Chemoresistant and Chemosensitive Acute. Myeloid Leukemia. Cytogenet Genome Res. 2013;141(4):272-6.Google Scholar
- Adams BD, Furneaux H, White BA. The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines. Mol Endocrinol. 2007;21(5):1132–47. doi:10.1210/me.2007-0022.PubMedGoogle Scholar
- Gambardella S, Rinaldi F, Lepore SM, Viola A, Loro E, Angelini C, et al. Overexpression of microRNA-206 in the skeletal muscle from myotonic dystrophy type 1 patients. J Transl Med. 2010;8(1):48.PubMedPubMed CentralGoogle Scholar
- Ma G, Wang Y, Li Y, Cui L, Zhao Y, Zhao B, et al. MiR-206, a key modulator of skeletal muscle development and disease. Int J Biol Sci. 2015;11(3):345–52. doi:10.7150/ijbs.10921.PubMedPubMed CentralGoogle Scholar
- Vimalraj S, Miranda PJ, Ramyakrishna B, Selvamurugan N. Regulation of breast cancer and bone metastasis by microRNAs. Dis Markers. 2013;35(5):369–87. doi:10.1155/2013/451248.PubMedPubMed CentralGoogle Scholar
- Bicker S, Lackinger M, Weiss K, Schratt G. MicroRNA-132, −134, and −138: a microRNA troika rules in neuronal dendrites. Cell Mol Life Sci. 2014;71(20):3987–4005. doi:10.1007/s00018-014-1671-7.PubMedGoogle Scholar
- Chen X, Yan Q, Li S, Zhou L, Yang H, Yang Y, et al. Expression of the tumor suppressor miR-206 is associated with cellular proliferative inhibition and impairs invasion in ERalpha-positive endometrioid adenocarcinoma. Cancer Lett. 2012;314(1):41–53. doi:10.1016/j.canlet.2011.09.014.PubMedGoogle Scholar
- Dereure O. Mutations in H-Ras proto-oncogen in Costello syndrome. Ann Dermatol Venereol. 2006;133(8–9 Pt 1):731.PubMedGoogle Scholar
- Paquin A, Hordo C, Kaplan DR, Miller FD. Costello syndrome H-Ras alleles regulate cortical development. Dev Biol. 2009;330(2):440–51. doi:10.1016/j.ydbio.2009.04.010.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.